Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels

Journal of the National Cancer Institute

Volumn 95, Issue 14, 2003, Pages 1044-1053

  Cramer, Scott D ^a   Chang, Bao Li ^a   Rao, Anuradha ^a   Hawkins, Gregory A ^a   Zheng, S Lilly ^a   Wade, Wendy N ^a   Cooke, Roger T ^a   Thomas, Leanne N ^a   Bleecker, Eugene R ^a   Catalona, William J ^b   Sterling, David A ^c   Meyers, Deborah A ^a   Ohar, Jill ^d   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; PROSTATE SPECIFIC ANTIGEN; BETA GALACTOSIDASE; TUMOR MARKER;

ADULT; ANALYSIS OF VARIANCE; ANTIGEN DETECTION; ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE ACTIVITY; GENE AMPLIFICATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE DISEASE; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; AGED; ALLELIC IMBALANCE; BLOOD; DNA SEQUENCE; GENETIC MARKER; GENETICS; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; PREVALENCE; PROSTATE TUMOR;

AGED; ALLELIC IMBALANCE; ANALYSIS OF VARIANCE; BETA-GALACTOSIDASE; CLONING, MOLECULAR; GENE AMPLIFICATION; GENETIC MARKERS; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LUCIFERASES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 0042594668     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.14.1044     Document Type: Article

References (34)

1. Sensabaugh G. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci 1978;23:106.
2. Sinha A, Wilson M, Gleason D. Immunoelectron microscopic localization of prostate-specific antigen in human prostate by the protein A-gold complex. Cancer 1987;60:1288-93.
3. Stamey T, Yang N, Hay A, McNeal J, Freiha F, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
4. Hara M, Inoue T, Koyanagi Y, Fukuyama T, Iki H. Immunochemical characteristics of human specific component "gamma-Sm" (in Japanese) [abstract]. Nippon Hoigaku Zasshi 1969;23:333.
5. Stamey T, Kabalin J. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141:1070-5.
6. Barry M. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001;344:1373-7.
7. Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270:860-4.
8. Morgan T, Jacobsen S, McCarthy W, Jacobson D, McLeod D, Moul J. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996;335:304-10.
9. Bassler T, Orozco R, Bassler I, O'Dowd G, Stamey T. Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Urology 1998;52: 1064-9.
10. Powell I, Banerjee M, Novallo M, Sakr W, Grignon D, Wood D, et al. Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol 2000; 163:146-9.
11. Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. J Urol 2002;168:504-8.
12. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol 2002;168:922-5.
13. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-61.
14. Schuur E, Henderson G, Kmetec L, Miller J, Lamparski H, Henderson D. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996;271:7043-51.
15. Pang S, Dannulli J, Kaboo R, Xie Y, Tso C, Michel K, et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997;57:495-7.
16. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996;271:6379-88.
17. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 1995;6: 1417-26.
18. Zhang S, Murtha PE, Young CY. Defining a functional androgen responsive element in the 5′ far upstream flanking region of the prostate-specific antigen gene. Biochem Biophys Res Commun 1997;231:784-8.
19. Zhang J, Zhang S, Murtha PE, Zhu W, Hou SS, Young CY. Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation. Nucleic Acids Res 1997;25:3143-50.
20. Huang W, Shostaki Y, Tarr P, Sawyers C, Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 1999;274:25756-68.
21. Rao A, Cramer S. Identification of a polymorphism in the ARE I region of the PSA promoter [abstract]. Cancer Res 1999;40:60.
22. Xue WM, Coetzee G, Ross R, Irvine R, Kolonel L, Henderson B, et al. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2001; 10:575-9.
23. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000;60: 839-41.
24. Medieros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliviera J, et al. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 2002; 53:88-94.
25. Xu J, Meyers D, Sterling D, Zheng S, Catalona W, Cramer S, et al. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 2002;11:664-9.
26. Rao A, Chang B, Hawkins G, Hu J, Rosser C, Hall M, et al. Analysis of the G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 2003;61:864-9.
27. Weir B. Genetic data analysis II: methods for discrete population genetic data. Boston (MA): Sinauer Association; 1996.
28. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-22.
29. Schaid D, Rowland C, Tines D, Jacobson R, Poland G. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
30. Stamey T. Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of preoperative PSA failure. Clin Chem 2001;47:631-4.
31. Stamey T, Johnstone I, McNeal J, Lu A, Yemoto C. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002;167: 103-11.
32. Cohen P, Peehl D, Graves H, Rosenfeld R. Biological effects of prostate specific antigen (PSA) as an IGF binding protein-3 (IGFBP-3) protease. J Endocrinol 1994;142:407-15.
33. Cramer S, Chen Z, Peehl D. Prostate specific antigen cleaves parathyroid hormone-related protein (PTHrP) in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156:526-31.
34. Zhao S, Dallas S, Peehl D, Cramer S, Bonewald L. Prostate-specific antigen is a potent activator of the 100 kDa latent TGFbeta. J Bone Miner Res 1997;12 (Suppl 1):S397.